

4DMedical strengthens executive team with CFO appointment

2 January 2026

Melbourne, Australia, 2 January 2026: 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”), a global leader in respiratory imaging technology, today announces the appointment of Julian Sutton as Chief Financial Officer (CFO) and Executive Director.

Julian is an early investor in 4DMedical and has served as a Non-Executive Director since September 2017, developing deep expertise in the Company's technology, strategy, and commercial operations. Over this period, he has worked closely with the executive team on capital strategy, corporate governance, and investor relations, playing an instrumental role in securing funding to advance the Company's product development, regulatory and commercial objectives.

Julian's appointment to the executive team follows a period of significant commercial momentum for 4DMedical. With CT:VQ™ now FDA-cleared and actively deployed at leading U.S. academic medical centres, and a transformative global distribution agreement with Philips recently announced, the Company is well positioned for accelerated scale-up. This appointment formalises Julian's strategic role at a pivotal inflection point in the Company's commercialisation.

4DMedical CEO and Founder, Andreas Fouras, said:

Julian has been a trusted adviser to 4DMedical for many years and has played an instrumental role in supporting the Company's growth, capital strategy and engagement with investors.

As the momentum behind CT:VQ™ continues to build, it is the right time to formalise Julian's role within the executive team. His deep understanding of the business, his capital markets expertise, and his long-standing working relationship with the whole management team will be invaluable as we scale globally.

Julian Sutton said:

4DMedical is entering a defining phase of its growth, with CT:VQ™ now FDA-cleared, commercially deployed at leading U.S. institutions, and supported by a major strategic partnership with Philips.

Having worked closely with Andreas and the Board since 2017, I have strong conviction in the technology and the opportunity ahead. I'm excited to step into the CFO role and help execute the Company's strategy as we focus on commercial scale-up and long-term shareholder value creation.

Further details of Julian's executive appointment, as required under ASX Listing Rule 3.16.4, are set out in Annexure A to this announcement.

—ENDS—

Authorised by the 4DMedical Board of Directors.



Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionising respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology**[®] transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS[®])**, **CT LVAS[™]**, and the ground-breaking **CT:VQ[™]** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalised patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com



Annexure A

Summary of material terms of Julian Sutton's appointment

Position:	Chief Financial Officer and Executive Director
Term:	3 years
Annual remuneration:	A\$427,000 per annum (exclusive of superannuation)
Incentives:	Eligible to participate in the Company's Short-Term Incentive (STI) and Long-Term Incentive (LTI) plans
Notice period:	3 months